Can Yas (specific medication) replace Angiotensin-Converting Enzyme (ACE) inhibitors for kidney protection in patients with diabetes and impaired renal function?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board

Educational purpose only • Exercise caution as content is pending human review

Article Review Status

Submitted

Under Review

Approved

Last updated: January 7, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Related Questions

In a Black adult with stage G3a chronic kidney disease (eGFR ≈ 52 mL/min/1.73 m²), normal albuminuria, pre‑diabetes, and a history of angio‑edema risk, should I start an ACE inhibitor or an angiotensin‑receptor blocker?

What is the optimal antihypertensive and diabetes regimen for an 88‑year‑old patient with type 2 diabetes mellitus, hypertension, no history of angioedema, no ACE‑inhibitor contraindication, and end‑stage renal disease (severe renal impairment)?

Are Angiotensin Receptor Blockers (ARBs) and Angiotensin-Converting Enzyme (ACE) inhibitors nephroprotective in the long term for patients with hypertension, heart failure, or chronic kidney disease, particularly those with diabetes?

What is the initial treatment for a patient with 2+ proteinuria?

What is the best management approach for a patient with chronic kidney disease (CKD) and significant proteinuria?

What is the safest antidepressant for an elderly patient with depression, sleep disturbances, and pain?

Is Targeted Drug Delivery (TDD) using preservative-free morphine (morphine) 0.1 milligram/milliliter, with procedure code 62327, medically indicated for a patient with Postlaminectomy syndrome and severe spasticity, and is this treatment experimental per the plan language?

What is the difference between Ferrous (iron) supplements, specifically Ferrogen, and Sucrin (possibly an iron supplement), in the treatment of iron deficiency anemia?

What is the most appropriate next step in management for a patient with a confirmed pseudocyst following severe pancreatitis, who is currently asymptomatic or mildly symptomatic with mild epigastric discomfort, bloating, loss of appetite, and epigastric fullness?

What are alternative treatment options for a patient with small intestine bacterial overgrowth (SIBO) who cannot take rifaxamin (Xifaxan)?

What monitoring is required when starting spironolactone in adult patients with heart failure, hypertension, or impaired renal function?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.